Eyewire+FDA Approves Rayner’s RayOne Galaxy Spiral IOL Platform

📋 Regulatory Action / Label Change

The FDA approved RayOne Galaxy and RayOne Galaxy Toric for US commercial availability, introducing Rayner’s non-diffractive spiral optic platform to US cataract surgeons. The approval followed an IDE study of more than 250 patients across 10 US sites. The platform is designed to provide continuous-range vision while limiting dysphotopsias associated with some presbyopia-correcting lenses. Although Rayner reports favorable safety and patient-reported findings, detailed comparative IDE results were not provided in this source.

Professional Impact

• The approval adds two spiral-optic IOL options, including a toric model, to the US cataract surgery market.
• The pivotal IDE program included more than 250 patients at 10 US clinical sites.
• The non-diffractive design is intended to provide a continuous range of vision without conventional diffractive rings or steps.
• Rayner reports low levels of bothersome dysphotopsia, but this article does not provide detailed comparative outcomes or effect estimates.
• More than 200,000 implants across 75 countries preceded the US approval, according to company-reported figures.
• US availability expands Rayner’s ophthalmic portfolio following recent FDA clearances for RayOne EMV Toric and the Sophi phacoemulsification system.

Action Items

• Review the FDA-approved indications and labeling when considering where the platform fits within existing IOL selection pathways.
• Evaluate published and regulatory evidence on visual range, dysphotopsia, contrast performance, and toric outcomes as detailed data become available.
• Discuss expected visual benefits and trade-offs within established preoperative counseling and shared decision-making workflows.
• Monitor post-launch clinical experience and comparative evidence against established presbyopia-correcting IOL technologies.